INTRODUCTION
Malaria is a common protozoan disease transmitted to humans by the Anopheles mosquito. Certain species Received for publication 16 September 1982 and in revised form 7 December 1982. ' Abbreviations used in this paper: APTT, activated partial thromboplastin time; DIC, disseminated intravascular coagulation; IRMA, immunoradiometric assay; PAIgG, platelet-associated IgG. of Plasmodia infect human erythrocytes and the growth and replication of the parasites leads to the rupture of the erythrocytes and the release of parasites into the circulation. Most patients develop malarialspecific antibodies after infection and the binding of antibodies to Plasmodium antigens results in circulating immune complexes (1) .
Malaria can cause hemostatic abnormalities that range from asymptomatic thrombocytopenia to fulminant disseminated intravascular coagulation (DIG),' (2) (3) (4) . Early investigators suggested that the major coagulation abnormality of malaria was DIC, but in recent years clinicians have recognized that thrombocytopenia is a common and early sign of malaria infections, whereas DIC is rare (3) (4) (5) . It has been estimated that "80% of patients infected with either P. vivax or P. falciparum malaria develop thrombocytopenia during their infection, and although the thrombocytopenia is caused by an increased platelet destruction, the mechanism hitherto has been unknown (4) (5) (6) (7) (8) . In this report we describe studies investigating the mechanism responsible for the thrombocytopenia of malaria.
METHODS

Patient studies
Patient population. Patients were considered to have malarial infections if they fulfilled the following criteria: (a) they had symptoms compatible with malaria infection including fever; (b) they had a history of exposure; and (c) intraerythrocyte parasites were observed on blood films.
Pooled convalescent patient sera were obtained from patients who had had recurrent P. falciparum infections. Control sera were obtained from healthy individuals who had never had malaria.
Measurement of platelet-associated IgG (PAIgG). PAIgG was measured on washed platelets collected from patients with malaria infections using the antiglobulin consumption assay of Dixon and Rosse with the modifications we have described (9) (10) (11) . The in vitro studies were performed using an immunoradiometric assay (IRMA) (12) . The In vitro studies
Preparation of P. falciparum antigen. P. falciparum (FCR3TC strain) was raised in continuous culture as has been described (13) . Human column (Pharmacia Fine Chemicals). The IgG-rich fraction was further purified by gel filtration across a 2.6 X 40 cm S-300 column, (Pharmacia Fine Chemicals). F(ab')2 was prepared from the IgG fractions by pepsin digestion followed by gel filtration across a 2.6 X 40-cm S-200 column (13) . The purity of the IgG and F(ab)2 was confirmed by Ouchterlony double diffusion immunoprecipitation and analytical polyacrylamide gel electrophoresis in SDS. Before use the preparations were ultracentrifuged (35,000 g X 120 min) to remove aggregates.
The intact and digested immunoglobulins were radiolabeled with '25iodine using lactoperoxidase Enzymobeads (Bio-Rad Laboratories Richmond, CA). After labeling, the unbound 125iodine was separated from the '251-immunoglobulin by gel filtration across a 1 X 25-cm Sephadex G-75 column. Protein determinations were made using the Bio-Rad technique.
Measurement of malaria-dependent binding of IgG to platelets. Malaria-dependent binding of IgG to control platelets was determined after incubating patient or control serum with control group 0 platelets in the presence and absence of unlabeled malarial antigen. The platelets were washed three times and the serum-platelet bindable IgG measured (14) , using the IRMA assay (12 
RESULTS
Patient studies 28 patients (26 P. vivax, 2 P. falciparum) had simultaneous platelet counts and PAIgG determinations performed at presentation (all using the antiglobulin consumption assay). 17 were thrombocytopenic (platelet count < 150,000/,ul) and 16 of the 17 had elevated PAIgG. 5 of the 11 nonthrombocytopenic patients also had elevated levels of PAIgG. There was an inverse relationship between the platelet count and PAIgG level in the patients, r = 0.635, P < 0.01 (Fig. 1) patients (nadir in platelet count of 16000-25,000/,Ml)
had serial fibrinopeptide A determinations performed during their hospitalization and all results were within the normal range for a hospitalized population (<3 pg/ml).
In vitro studies Malarial-dependent binding of IgG to platelets. The incubation of patient serum with 100 ug of malarial antigen resulted in a significant increase in the binding of IgG to control platelets (Table I ). This IgG was firmly bound and resisted multiple (three) washings. In contrast, control serum plus malarial antigen did not result in the increased binding of IgG to platelets, nor was there increased binding of patient serum to control platelets in the absence of malarial antigen. There was no pelletable precipitate formed by the incubation of malaria antigen and patient serum.
Binding of malarial antigen to platelets. Malarial antigen firmly bound to platelets in a dose-dependent fashion (Fig. 2) . Experiments were performed using incubation times of 60, 120, and 180 min and all demonstrated that the reaction was complete by 60 +, indicates included in the experiment. no precipitate (immune complex) was noted. n, number of experiments, each using four dilutions of platelets. Serum-platelet bindable IgG (S-PBIgG) was measured on three times washed platelets using the IRMA assay. The patient serum was a pool of several sera collected from patients with recurrent P. falciparum infections.
ing concentrations of malarial antigen up to 18 yg resulted in increasing binding of '25I-patient IgG to platelets. Higher concentrations of malarial antigen were associated with less binding (Fig. 3) . Less than 1% of '25I-IgG prepared from control serum bound to platelets at any concentration of malarial antigen. It has been recognized for many years that the majority of patients with malarial infections have thrombocytopenia, but the mechanism of the thrombocytopenia -. ----,~--, , CL) 10 -17) of the thrombocytopenic patients had elevated levels of PAIgG during the thrombocytopenic episode. The PAIgG returned to normal as the thrombocytopenia resolved, and while the patient continued on the same antimalaria drugs, indicating that the thrombocytopenia was not drug induced. Elevated levels of PAIgG were also noted in 5 of 11 nonthrombocytopenic patients and these patients may have been in a compensated thrombocytolytic state (Fig. 1) . There are several mechanisms that could account for the elevated PAIgG observed in patients with malaria and these are illustrated diagrammatically in Fig. 4 . The possibility of nonspecific uptake of IgG by platelets damaged by malarial antigens was excluded by the demonstration that incubation of platelets and malarial antigen with control serum did not result in the binding of IgG to these platelets (Table I) . Increased binding of IgG to control platelets occurred only when convalescent patient serum was incubated with malarial antigen and platelets. The increased PAIgG could represent immune complexes adsorbed to platelet Fc receptors. Consistent with this hypothesis is the observation that patients with malarial infection frequently have circulating immune complexes (1). Alternatively, immune IgG could bind to platelet-bound malarial antigen, (Fig.  4) . Indirect support for this latter hypothesis was provided by the demonstration that platelets have saturable binding sites for malarial antigen (Fig. 2) . Increasing concentrations of malarial antigen were able to displace platelet-bound patient IgG. It was not determined why the IgG was displaced by concentrations of malarial antigen below that needed to saturate all platelet binding sites. The latter observation is consistent with either immune complex binding or immunoglobulin binding to platelet-bound malarial antigen.
To resolve this issue the malaria-dependent binding of intact patient IgG was related to the binding of the same IgG after enzymatic destruction of the Fc terminus to produce F(ab')2. These molecules would be unable to bind to the platelet Fc receptors and hence could be used to assay the relative contribution of immune complexes to the platelet-bound immunoglobulin. We found that the relative binding of patient IgG and F(ab')2 was very similar and dependent upon the presence of malarial antigen.
In summary, in at least some patients with malaria, the thrombocytopenia is caused by immune mechanisms. Immune complexes are not responsible for the elevated platelet-bound immunoglobulin, rather, IgG binds to platelet-associated malarial antigen through its Fab terminus.
